Factor IX Dosing
Loading...
%
%
References
- Sjoerd F Koopman. Relationship between Dose, Factor IX Activity Levels and Bleeding Probability for rIX-FP Prophylaxis in Hemophilia B: A Repeated Time-to-Event Analysis.. Clinical pharmacology and therapeutics, 2025
- Suely M Rezende. International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.. Journal of thrombosis and haemostasis : JTH, 2024
- Steven W Pipe. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B.. The New England journal of medicine, 2023
- E. Santagostino. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial.. Blood, 2016
- J. Powell. Long‐acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B‐LONG study. British Journal of Haematology, 2015
- M. Xi. Systematic Review of the Published Evidence on the Pharmacokinetic Characteristics of Factor VIII and IX Concentrates. Blood, 2014
- J. Powell. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B.. The New England journal of medicine, 2013
- D. Roth. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.. Blood, 2001